AstraZeneca, German firm to try speeding vaccine delivery
Drugmaker AstraZeneca says it will work with German firm IDT Biologika to increase shipments of its COVID-19 vaccine to the European Union this spring following a heated dispute with the bloc over delayed vaccine deliveries
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Drugmaker AstraZeneca says it will work with German firm IDT Biologika to increase shipments of its COVID-19 vaccine to the European Union this spring following a heated dispute with the bloc over delayed vaccine deliveries.
The Anglo-Swedish company said Wednesday that the two companies were “exploring options” to accelerate production of the vaccine in the second quarter of this year. AstraZeneca is already involved in the production of vaccines with IDT.
In the longer term, AstraZeneca also plans a joint investment to expand IDT Biologika’s plant in Dessau, Germany, by building up to five 2,000-liter bioreactors capable of making tens of millions of doses of vaccine each month, the companies said. The additional capacity is expected to be operational by the end of 2022. IDT Biologika said the extent of AstraZeneca’s participation in the project is subject to future negotiations.
“This agreement will greatly help Europe build an independent vaccine manufacturing capability that will allow it to meet the challenges of the current pandemic and create strategic supply capacity for the future,’’ AstraZeneca CEO Pascal Soriot said. “We are delighted to be investing with our partner IDT Biologika in the future health, security and wellbeing of millions of citizens across Europe.
The announcement comes after EU leaders demanded that AstraZeneca live up to its contracts with the bloc following the drugmaker’s announcement that it was reducing initial shipments of the COVID-19 vaccine due to production issues.